Business Context and Reporting Period
This Form 8-K Current Report was filed by Artelo Biosciences, Inc. on December 3, 2021. The company is a Nevada corporation with principal executive offices in Solana Beach, California. Its common stock (ARTL) and warrants (ARTLW) are registered on The Nasdaq Stock Market, LLC.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on a specific corporate governance event regarding executive compensation.
Material Changes
The material event reported is the grant of a stock option to the Company's Principal Executive Officer, Gregory D. Gorgas, on December 3, 2021, under the 2018 Equity Incentive Plan.
- Option Size: 1,355,000 shares of common stock.
- Exercise Price: $0.63 per share.
- Vesting Schedule: 25% vests on December 3, 2022, with the remaining balance vesting ratably monthly over a 36-month period thereafter.
- Conditions: Vesting is contingent upon Mr. Gorgas remaining a Service Provider through each applicable vesting date.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on future operations, or specific risk factors beyond the standard terms of the equity plan. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the current share price relative to the $0.63 exercise price to assess the option's intrinsic value.
- Review the full terms of the 2018 Equity Incentive Plan for additional restrictions or acceleration clauses.
- Confirm Mr. Gorgas's continued employment status to ensure vesting conditions are met.
- Check subsequent filings for any dilution impact on existing shareholders from this grant.